TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04018885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 2.5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 2.5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 2.5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 5%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 10%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 10%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 10%
Description: Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
Study: NCT01796223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT01395849

Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Study: NCT00695136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase REM sleep percentage
Study: NCT03300609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01744743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: levothyroxine
Description: Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levothyroxine
Description: Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
Study: NCT04249050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact powder
Description: Oral nutritional supplement containing fish oil, arginine and RNA
Study: NCT02448498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Study: NCT01346462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Centered Transition Intervention
Description: Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
Study: NCT02531399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOCT
Description: Measurement of retinal blood velocities

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDV
Description: Measurement of retinal blood velocities

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVA
Description: Measurement of retinal vessel diameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSFG
Description: Imaging of retinal blood flow
Study: NCT00130910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole 400mg x 3 first dose observed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Albendazole Placebo 400mg x 3 first dose observed
Study: NCT00601822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Description: CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
Study: NCT01688453

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care management
Description: The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care management
Description: The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The strengthened care management
Description: The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation.
Study: NCT00008320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceramide
Study: NCT02572635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PnuBioVax
Description: Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PnuBioVax
Description: Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PnuBioVax
Description: Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
Study: NCT02979171

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway Classic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway Classic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway Classic
Study: NCT03440047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Flim Processor VP-7000, Light Source BL-7000
Description: Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
Study: NCT02311777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin will be given orally during preoperative period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be given on the surgery day before the anesthesia induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally during preoperative period
Study: NCT01979289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized cognitive remediation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computerized cognitive remediation:Control
Study: NCT03964181

Intervention type: OTHER
Intervention: Change in school start times
Description: Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.

Intervention type: OTHER
Intervention: Change in school start times
Description: Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.

Intervention type: OTHER
Intervention: Change in school start times
Description: Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
Study: NCT01875341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP; Nasal continuous positive airway pressure.
Description: Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NCPAP; Nasal continuous positive airway pressure.
Description: Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
Description: In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group
Description: In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
Study: NCT05365087

Intervention type: PROCEDURE
Intervention: Transoral Fundoplication and Sleeve Gastrectomy
Description: Transoral Fundoplication procedure completed prior to Sleeve Gastrectomy

Intervention type: PROCEDURE
Intervention: Gastric Bypass
Description: Laparoscopic Roux-en-Y gastric bypass
Study: NCT00384865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg, taken orally, once a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg, taken orally, once a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg, taken orally, once a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg, taken orally, once a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, taken orally, once a day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken orally, once a day for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, taken orally, once a day for 6 months
Study: NCT01093599

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit Line plus MTS
Description: This provides the quit line intervention plus the Mindfulness for Smokers Intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit Line Only
Description: The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
Study: NCT00779064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 10mg BID, Semi-sequential, dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 20mg BID, Semi-sequential, dose escalation.
Study: NCT02475876

Intervention type: DRUG
Group type: OTHER
Intervention: Clindamycin
Description: Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose =10 mg/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: trimethoprim-sulfamethoxazole
Description: Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose = 6 mg/kg.~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose = 6 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose = 6 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose = 6 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose = 4 mg/kg.
Study: NCT03376698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg
Description: oral administration of Colchicine 0.5 mg once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.25 mg
Description: oral administration of Colchicine 0.25 mg once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of Placebo once daily for 12 weeks
Study: NCT03592498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadiazine, Silver
Description: Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin of Nile tilapia
Description: Application of skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
Study: NCT01969084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcirculation testing
Description: The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcirculation testing
Description: The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macrocirculation testing
Description: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Macrocirculation testing
Description: Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Scans
Description: Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI Scans
Description: Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
Study: NCT03391804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177
Description: ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
Study: NCT03985488

Intervention type: RADIATION
Intervention: Radiation exposure
Description: Radiation exposure via Eview Fluoroscopy machine.

Intervention type: RADIATION
Intervention: Radiation exposure
Description: Radiation exposure via Eview Fluoroscopy machine.